Purchase Print Copy

 FormatList Price
Add to Cart Paperback6 pages Free

Evidence suggests that insurers limit access to clinical trials because of cost concerns. Denial of coverage for treatment in a clinical trial limits patient access to trials and could limit clinical research. Public and private efforts are underway to change these policies, but their status is unclear, although preliminary estimates suggest that such changes would not be expensive. Previous studies found that treatment costs in clinical trials are similar to costs of standard therapy; however, it is difficult to generalize from these studies. As part of the Cost of Cancer Treatment Study, an ongoing effort to produce generalizable estimates of the incremental costs of government-sponsored cancer trials, the authors are conducting a one-year retrospective study of costs for 1,500 cancer patients recruited from a randomly selected sample of institutions in the U.S. The results of the study should be of great interest to insurers and the research community as they consider permanent ways to finance cancer trials.

Originally published in: Journal of Clinical Oncology, v. 19, no. 1, January 1, 2001, pp. 105-110.

This report is part of the RAND Corporation Reprint series. The Reprint was a product of the RAND Corporation from 1992 to 2011 that represented previously published journal articles, book chapters, and reports with the permission of the publisher. RAND reprints were formally reviewed in accordance with the publisher's editorial policy and compliant with RAND's rigorous quality assurance standards for quality and objectivity. For select current RAND journal articles, see External Publications.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.